Ethyl 2-((Tert-Butoxycarbonylamino)Methyl)Thiazole-4-Carboxylate

When Boc Deprotection Outpaces Hydrolysis: Process Intensification in NS5A Inhibitor Synthesis

Ethyl 2-((tert-butoxycarbonylamino)methyl)thiazole-4-carboxylate serves as the principal amine-building block in convergent fragment-based assembly pathways targeting hepatitis C virus NS5A replication complex inhibitors. The molecule is integrated downstream as the 2-aminomethyl-thiazole-4-carbonyl segment, which occupies the zone-3 hydrophobic pocket in lead candidates structurally analogous to pibrentasvir-type macrocyclic architectures. Industry compliance for intermediates delivered at this stage follows ICH Q7 Section 8.3 for critical process parameters validated across three consecutive manufacturing lots. Residual palladium and copper catalysts—introduced during the preceding thiazole ring-closure—are controlled by a dedicated graphite-furnace atomic absorption spectroscopy method with limits set below 10 ppm Pd and 25 ppm Cu, per Ph. Eur. 5.20. The stock intermediate is charged at a molar ratio of 1.05 equivalents relative to the heptapeptidomimetic acid coupling partner to compensate for minor losses during in-line water wash equilibration. In a 1000-L glass-lined reactor equipped with retreat-blade impeller and divided-volume jacket, batch processing proceeds via simultaneous ester saponification and Boc deprotection. Lithium hydroxide monohydrate (2.5 eq) in a water/tetrahydrofuran/methanol ternary mixture (2:1:1 by volume) held at 18 °C ± 2 °C cleaves the ethyl ester heterogeneously over 6 hours, after which the temperature is raised to 28 °C and trifluoroacetic acid (8.0 eq) is metered over 45 minutes to strip the Boc group. The sequence is monitored by process Raman spectroscopy tracking the 1754 cm⁻¹ ester carbonyl stretch and the 1698 cm⁻¹ carbamate carbonyl band. Post-quench phase separation with isopropyl acetate preserves the free amino acid as the crystalline TFA hemihydrate salt, facilitating filtration through a 0.45 µm in-line filter. Terminal products are oral film-coated tablets dosed at 90 mg freebase equivalent in fixed-dose combinations with sofosbuvir, identified under USP Monograph sections for related-compound substances.

Gradient-Dependent Coupling Efficiency of Ethyl 2-((Boc-amino)methyl)thiazole-4-carboxylate with Chiral Amino Alcohols

An application domain in glycopeptide antibiotic side-chain elaboration exploits the ethyl ester as a masked electrophilic handle while the Boc group remains intact. The scaffold is reacted under Schotten-Baumann conditions with the amino-alcohol port of a teicoplanin-core aglycone in anhydrous tetrahydrofuran, where the water content is kept below 200 ppm by molecular sieve drying. The recipe-mandated addition ratio is 0.98 equivalents of the thiazole ester per mole of aglycone amino functionality to avoid over-acylation of the phenolic hydroxyls, which would trigger EMA/CHMP-mandated reprocessing limits for critical impurity E (≤ 0.15% area-normalized HPLC). A gradient vessel controller (Büchi CR-20) dispenses the ester solution over 120 minutes while the jacket temperature holds at −5 °C, suppressing the competing O→N acyl migration pathway that accelerates above 0 °C. The ethyl ester is then selectively hydrolysed using porcine pancreatic lipase type II suspended in phosphate buffer pH 7.2 with a catalyst loading of 12 wt% relative to ester mass, negating the need for alkaline conditions that would epimerize the aglycone’s D-chloroeremomycin unit. ISO 13408-6:2021 governs aseptic processing qualification for the final freeze-dried injectable product, which is reconstituted as a 500 mg infusion bag indicated for complicated skin and skin-structure infections caused by MRSA.

Long-standing manufacturing campaigns for Factor Xa direct inhibitors that incorporate a 2-aminomethylthiazole-4-carboxamide warhead have relied on a serial workflow where the fully deprotected amino acid is generated ex situ, isolated as a lyophilized solid, and subjected to amide coupling with an ortho-disubstituted aromatic amine. In a five-campaign dataset compiled under FDA 21 CFR Part 211.180(e) batch record review, operators reported a 23–27% mass loss between dry-solid isolation and charging due to electrostatic adhesion to anti-static PE liners, prompting a telescoped protocol. The thiazole ethyl ester is now received at the solid-dose API facility with a Certificate of Analysis confirming purity ≥ 99.5% (HPLC, area% at 254 nm), residual ethyl acetate ≤ 50 ppm (USP <467> Class 3). One batch of 150 kg enters the hydrolysis vessel as a single charge with 250 L ethanol and 120 L 6N hydrochloric acid; the solution is refluxed at 78 ± 1 °C for 4.5 hours. After solvent swap to dimethylformamide, the mixture is cooled to −10 °C and treated with 1.12 eq methanesulfonic acid to form the mesylate salt in situ, shifting the amine protonation state and preventing aza-Michael dimerization detected via LCMS at m/z 513.2. Coupling to pyridine-2-carboximidamide proceeds using O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (1.18 eq) and N,N-diisopropylethylamine (3.0 eq) with a crystallization pulse seeded at 42 °C. The final anticoagulant active substance, supplied as a 2.5 mg tablet, complies with the Ph. Eur. monograph 2598 for Edoxaban-related substances and is manufactured under ISO 14001:2015 site certification.

At What pH Does the Thiazole Ring Tolerate Alkaline Ester Hydrolysis Without Ring-Scission?

A dedicated quality-by-design landscape exists around the saponification of ethyl 2-((tert-butoxycarbonylamino)methyl)thiazole-4-carboxylate for oncology kinase inhibitor payloads, where the destination molecule is a mesylate salt of a 2-aminomethylthiazole-4-carboxamide appended to an acryloylpiperidine electrophile. The process challenge originates in the thiazole ring’s susceptibility to hydroxide-mediated opening at the C2−N3 bond when the pH exceeds 12.5 at temperatures above 35 °C, generating a β-mercapto enamide that irreversibly escapes crystallization and elevates total organic carbon in waste streams beyond the 50 mg/L discharge consent set by EU Directive 2010/75/EU. A two-step saponification protocol was filed under USPTO DMF 035418, where the ester is first treated with potassium trimethylsilanolate (1.35 eq) in tetrahydrofuran‑acetonitrile (4:1) at 22 °C for 40 minutes; this mild nucleophile cleaves the ethyl ester with > 99% selectivity while leaving the Boc group unaffected. The transient potassium carboxylate is then acidified with 3N HCl to pH 3.7, triggering decarboxylation of the Boc group and liberating the free amine as a crystalline hydrochloride. Unwanted ring-opened species are monitored via UPLC with a Waters ACQUITY BEH C8 column (1.7 µm, 2.1×100 mm) using ion-pairing mobile phase of 10 mM heptafluorobutyric acid in water/acetonitrile (98:2 to 10:90 gradient over 14 minutes). The resulting amino acid hydrochloride is immediately coupled to 4-(acryloyl)piperidine-1-carbonyl chloride at a stoichiometric ratio of 1:1.02 in dimethylacetamide at −15 °C to form the targeted irreversible covalent kinase inhibitor, indicated for non-small cell lung cancers harbouring EGFR exon 20 insertion mutations. Batch release tests observe ICH Q3C Option 1 limits for residual dimethylacetamide (≤ 1090 ppm) and acetonitrile (≤ 410 ppm).

Thermal Lability of the Boc-Carbamate During Vacuum-Assisted Spray Drying of an Amorphous Polymer Dispersion

Ethyl 2-((tert-butoxycarbonylamino)methyl)thiazole-4-carboxylate is occasionally employed not as a building-block intermediate but as a pre-protected derivative that undergoes co-processing with hydroxypropyl methylcellulose acetate succinate (HPMCAS, grade LMP, substitution value 9% acetyl, 11% succinoyl) in a hot-melt extruder to produce a solid amorphous dispersion of a poorly soluble thiazole-based BCS class II drug candidate. The thiazole intermediate is first converted to the acid form via a lipase-catalysed hydrolysis that retains the Boc group, then spray-dried from a 15 wt% solution in acetone-water (85:15 v/v) using a Niro Mobile Minor™ spray dryer with a two-fluid nozzle atomising at 2.0 bar and an inlet temperature of 140 °C. The primary concern is the solid-state thermolysis of the Boc group, which has been observed by modulated differential scanning calorimetry (MDSC) to onset at 138 °C under a nitrogen sweep of 50 mL/min. Adjusting the inlet temperature downward to 128 ± 1 °C while elevating the feed rate to 42 g/min reduces the outlet particle temperature to 67–71 °C, measured by an in-cyclone thermocouple, and maintains residual Boc content above 98.5% as verified by ¹³C CP/MAS solid-state NMR integrating the 28.4 ppm tert-butyl resonance. The resultant amorphous dispersion is blended with croscarmellose sodium (3.0% w/w) and compressed on a Korsch XL 100 rotary press at a compression force of 12 kN to yield 300 mg tablets that release the drug substance under USP Apparatus II conditions at 75 rpm in pH 6.8 phosphate buffer, achieving 83% dissolution at 45 minutes.

In agrochemical pilot-plant batches targeting succinate dehydrogenase inhibitor (SDHI) fungicides structurally related to thifluzamide, ethyl 2-((tert-butoxycarbonylamino)methyl)thiazole-4-carboxylate provides the heterocyclic core without requiring the end-user’s handling of unstable thioamide precursors. The silo plant receives the ester in 25 kg fibre drums under a nitrogen blanket, accompanied by a REACH exposure scenario confirming a predicted no-effect concentration (PNEC) in freshwater of 8.2 µg/L. The downstream process integrates ester hydrazinolysis with hydrazine monohydrate (1.2 eq) in ethanol at reflux for 3 hours, forming the corresponding hydrazide, which undergoes subsequent condensation with 2-trifluoromethylbenzoyl chloride (1.10 eq) in the presence of triethylamine (1.4 eq) at 0–5 °C to yield the SDHI pharmacophore. The Boc protection remains through the hydrazide stage and is cleaved with formic acid (95% w/w) at 40 °C over 80 minutes, releasing the free amine that is instantaneously converted to a methylsulfonamide by reaction with methanesulfonyl chloride (1.25 eq). The final crystalline technical-grade product is isolated via a plate-and-frame filter press, washed with deionised water until conductivity drops below 50 µS/cm, and dried in a conical vacuum dryer at 50 mbar absolute pressure with a jacket temperature of 55 °C until the loss on drying is ≤ 0.5%. The fungicide is formulated as a 500 g/L suspension concentrate (SC) and registered under FAO Specification 406/SC. A key environmental compliance checkpoint under EU Regulation 283/2013 Annex III, Point 8.1.1 mandates that the parent ester intermediate must be monitored in aqueous processing effluent at a limit of quantification of 0.01 µg/L via SPE-LC-MS/MS, a threshold routinely verified by external ISO/IEC 17025:2017-accredited laboratories.

Lithium salt-mediated direct aminolysis has been adapted for the parallel synthesis of fragment libraries in neglected-disease trypanosomal workflows where the thiazole-4-carboxylate is converted into arrays of secondary amides without isolating the free acid. Ethyl 2-((tert-butoxycarbonylamino)methyl)thiazole-4-carboxylate, with a certified purity of 99.7% (HPLC, 210 nm) and a heaviest single impurity < 0.08%, is dissolved in anhydrous tetrahydrofuran and treated with lithium hexamethyldisilazide (1.0 M in THF, 1.02 eq) at −40 °C, generating a lithium amide-ester intermediate. After 15 minutes ageing, a primary aliphatic amine (e.g., 2-(pyrrolidin-1-yl)ethanamine) is added in a stoichiometry of 1.15 equivalents relative to the ester. The mixture is held at 0 °C for 3 hours before quenching with saturated ammonium chloride. This direct aminolysis avoids moisture ingress, which would precipitate lithium hydroxide and catalyse competing ester hydrolysis, and is executed under a nitrogen-purge glovebox maintaining < 5 ppm H₂O. The protective Boc group is cleaved in a subsequent step by dissolving the crude amide in 4N HCl in cyclopentyl methyl ether, isolating the product as the hygroscopic dihydrochloride salt. The microsomal stability assay (human liver microsomes, 0.5 mg/mL protein, 37 °C) of the resulting diamine-thiazole fragment yields a clearance half-life of 87 min. The complete batch record is archived under ISO 9001:2015 documentation and is available for client-side technology transfer as a pre-validated chemistry manufacturing and control package module 3.2.S.2.3 per ICH M4Q Common Technical Document format.